Published in Br J Psychiatry on February 01, 2001
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ (2002) 2.74
The occurrence of cannabis use disorders and other cannabis-related problems among first-year college students. Addict Behav (2007) 2.11
Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc (2012) 1.79
Adolescent brain development and the risk for alcohol and other drug problems. Neuropsychol Rev (2010) 1.71
Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology (2014) 1.54
Cannabis control: costs outweigh the benefits. For. BMJ (2002) 1.47
The relationship between bipolar disorder and cannabis use in daily life: an experience sampling study. PLoS One (2015) 1.42
"I Can Remember Sort of Vivid People…but to Me They Were Plasticine." Delusions on the Intensive Care Unit: What Do Patients Think Is Going On? PLoS One (2016) 1.39
Neurocognitive correlates of white matter quality in adolescent substance users. Brain Cogn (2009) 1.10
Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol (2009) 1.08
Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology (Berl) (2007) 1.07
5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol (2009) 1.05
Affect dysregulation in cannabis abusers: a study in adolescents and young adults. Eur Child Adolesc Psychiatry (2008) 0.99
Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin Pract Epidemiol Ment Health (2006) 0.98
Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther (2011) 0.97
Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav (2010) 0.94
Two cases of "cannabis acute psychosis" following the administration of oral cannabis. BMC Psychiatry (2005) 0.94
The endocannabinoid system as a target for modelling psychosis. Psychopharmacology (Berl) (2009) 0.87
A possible role for the endocannabinoid system in the neurobiology of depression. Clin Pract Epidemiol Ment Health (2007) 0.87
Cannabinoid CB1 receptor-mediated impairment of visuospatial attention in the rat. Psychopharmacology (Berl) (2004) 0.86
Avoiding emotional bonds: an examination of the dimensions of therapeutic alliance among cannabis users. Front Psychiatry (2013) 0.86
Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects. Eur Arch Psychiatry Clin Neurosci (2009) 0.85
Visual scan paths in first-episode schizophrenia and cannabis-induced psychosis. J Psychiatry Neurosci (2007) 0.83
Chronic Δ⁹-tetrahydrocannabinol exposure induces a sensitization of dopamine D₂/₃ receptors in the mesoaccumbens and nigrostriatal systems. Neuropsychopharmacology (2012) 0.82
Heavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analyses. Mol Psychiatry (2008) 0.82
Getting higher: co-occurring drug use among marijuana-using emerging adults. J Addict Dis (2014) 0.81
Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial. Psychopharmacology (Berl) (2014) 0.81
(AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population. Eur Arch Psychiatry Clin Neurosci (2006) 0.81
Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.81
Effects of eye dominance (left vs. right) and cannabis use on intermanual coordination and negative symptoms in schizophrenia patients. Eur Arch Psychiatry Clin Neurosci (2014) 0.81
Structural network topology revealed by white matter tractography in cannabis users: a graph theoretical analysis. Brain Connect (2012) 0.80
Comorbid mood, psychosis, and marijuana abuse disorders: a theoretical review. J Addict Dis (2009) 0.80
Cannabinoid abuse and addiction: Clinical and preclinical findings. Clin Pharmacol Ther (2015) 0.80
Involvement of opioid system in cognitive deficits induced by ∆⁹-tetrahydrocannabinol in rats. Psychopharmacology (Berl) (2011) 0.80
The relationship between cannabis involvement and suicidal thoughts and behaviors. Drug Alcohol Depend (2015) 0.79
Cannabis and psychopathology : update 2004. Indian J Psychiatry (2004) 0.78
Pragmatic approach to the dangers of cannabis use. Br J Psychiatry (2001) 0.78
Cannabinoid modulation of amygdala subregion functional connectivity to social signals of threat. Int J Neuropsychopharmacol (2014) 0.78
Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. Harm Reduct J (2012) 0.77
Psychiatric morbidity of cannabis abuse. Indian J Psychiatry (2003) 0.77
Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis. Neurotherapeutics (2015) 0.76
Marijuana for Glaucoma: A Recipe for Disaster or Treatment? Yale J Biol Med (2015) 0.75
Cannabis Use in Psychiatrie Patients. Med J Armed Forces India (2011) 0.75
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther Adv Neurol Disord (2016) 0.75
Cannabis and development of dual diagnoses: A literature review. Am J Drug Alcohol Abuse (2016) 0.75
Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis. Pharmaceuticals (Basel) (2010) 0.75
Role of vasopressin V1a receptor in ∆(9)-tetrahydrocannabinol-induced cataleptic immobilization in mice. Psychopharmacology (Berl) (2017) 0.75